Elon Musk’s preschool is the next step in his anti-woke education dreamsAt one point on Sunday, the Indianapolis Colts had a 38-7 lead over the Tennessee Titans in the second half. Usually, that's a sure sign you're coasting to a comfortable win. But flash forward to the 2-minute warning at the end of the 4th quarter, and there was nothing comfortable about it. The Colts lead had been cut down to 38-30, and Indianapolis was trying to put together a drive that would bleed the clock out. On 3rd & 8 on the IND 34 yard line, the Colts had to convert or else they'd risk the Titans getting the ball back with a little under 2 minutes to play. Anthony Richardson ended up finding Michael Pittman Jr. wide open at the boundary for an easy 1st that effectively put the game out of reach for Tennessee. In the moment, many were upset and confused seeing rookie CB Jarvis Brownlee Jr. playing with such a significant cushion against Pittman, seemingly gifting Indy the 1st and ending their chance to complete the comeback. But Titans legend Blaine Bishop broke down the truth of what happened on his 104.5 The Zone radio show Cover 2 on Monday. In Bishop's eyes, Brownlee is being unfairly criticized on the play. "That was a tough one there. I think they really out-coached us more so than anything else, even though that's how it looks there". Bishop went into detail on the play call and assignments he saw on the critical snap: "Well, the stuff they did, I think the Titans were expecting some form of an inside route. They played robber, which is one rover with one of the safeties coming down, robber in the middle of the field. So they probably show some things through, you know, studying them on that down and they didn't have the bunch. Initially, Pittman kind of motioned out a little bit. So he got like four yards or so from the bunch. So it's now two guys and then Pittman on his own. So it was really hard for him to be up on them. And they were playing zone, some form of a flat curl by (Roger) McCreary. And then Brownlee is supposed to be deep third. So to be honest, it's supposed to be the throw over McCreary's head. And then Brownlee is supposed to be over the top of that." In summary, Brownlee's assignment on this concept is the deep third of the field. He's responsible for keeping everything on that side of the field in front of him and picking up any vertical routes. McCreary, the underneath defensive back on the play who is put into conflict by the bunch formation and the routes run out of it, is likely more responsible for covering Pittman on that out-breaking route than Brownlee. But the way the way it plays out in real time to the untrained eye, it looks like Brownlee is just asleep on his man. "So unfairly or justified, I don't think he could have gotten up there. The other side was playing man. So they were in press. I think just because of the formation of bunch, then it was going to be hard to be in-between." Bishop can speak on this topic with authority because, as he put it, "I've been that flat curl person" which is what McCreary was on the play. "And Samari Rolle would be like, 'dang man...you going to get that out? Because it looks like I'm getting toasted because people are going to assume that that's my guy!' And I couldn't get out there in time and like, and they can throw it right on the sideline and I'm almost there and it's going right past my fingertips. And I could have just ran out there immediately. You can't miss a timing route. So they had a great play call. I can't blame (Brownlee)." This article first appeared on A to Z Sports and was syndicated with permission.ST. SIMONS ISLAND, Ga. (AP) — Maverick McNealy steadied himself after a rugged start Saturday with a 4-under 66 and caught up with Vince Whaley in a wild third round at the RSM Classic in which a half-dozen players had at least a share of the lead. McNealy looked as though he might have the lead when he hit wedge on the final hole that rolled just by the cup and settled 8 feet away. He missed the putt, still in great position to go after his first PGA Tour victory.mnl168 link 。

GSA Capital Partners LLP reduced its stake in Exelixis, Inc. ( NASDAQ:EXEL – Free Report ) by 81.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,708 shares of the biotechnology company’s stock after selling 52,983 shares during the quarter. GSA Capital Partners LLP’s holdings in Exelixis were worth $304,000 at the end of the most recent reporting period. Other institutional investors have also recently added to or reduced their stakes in the company. Farallon Capital Management LLC grew its holdings in Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after buying an additional 424,000 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Exelixis by 0.4% during the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after purchasing an additional 61,350 shares during the period. LSV Asset Management grew its holdings in Exelixis by 107.7% during the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock valued at $115,434,000 after purchasing an additional 349,837 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Exelixis by 12.7% in the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock valued at $73,425,000 after purchasing an additional 370,199 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades EXEL has been the subject of several recent research reports. Wells Fargo & Company lifted their price target on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Truist Financial lifted their price objective on Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. UBS Group initiated coverage on Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. Finally, Piper Sandler upped their target price on Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $31.44. Insider Buying and Selling at Exelixis In other Exelixis news, EVP Jeffrey Hessekiel sold 20,000 shares of Exelixis stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Also, EVP Dana Aftab sold 1,162 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now owns 498,945 shares in the company, valued at $15,666,873. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here . Insiders sold a total of 289,736 shares of company stock valued at $9,471,510 in the last ninety days. Corporate insiders own 2.85% of the company’s stock. Exelixis Stock Performance Shares of Exelixis stock opened at $35.61 on Friday. Exelixis, Inc. has a one year low of $19.20 and a one year high of $36.60. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 0.87 and a beta of 0.51. The stock has a 50 day moving average price of $29.90 and a 200-day moving average price of $25.57. Exelixis ( NASDAQ:EXEL – Get Free Report ) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Exelixis’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. Sell-side analysts predict that Exelixis, Inc. will post 1.68 earnings per share for the current fiscal year. Exelixis Profile ( Free Report ) Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Featured Stories Five stocks we like better than Exelixis 5 discounted opportunities for dividend growth investors Tesla Investors Continue to Profit From the Trump Trade NYSE Stocks Give Investors a Variety of Quality Options MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally What is the Hang Seng index? Netflix Ventures Into Live Sports, Driving Stock Momentum Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. ( NASDAQ:EXEL – Free Report ). Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter .

Former Titans great reveals truth behind back-breaking moment in loss to Colts

ST. SIMONS ISLAND, Ga. (AP) — Maverick McNealy steadied himself after a rugged start Saturday with a 4-under 66 and caught up with Vince Whaley in a wild third round at the RSM Classic in which a half-dozen players had at least a share of the lead. McNealy looked as though he might have the lead when he hit wedge on the final hole that rolled just by the cup and settled 8 feet away. He missed the putt, still in great position to go after his first PGA Tour victory. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Inside the Gaetz ethics report, a trove of new details alleging payments for sex and drug use

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Hold” by Brokerages